[Adjuvant chemotherapy and/or hormone therapy after radical prostatectomy for high-risk prostate cancer].
Cancer prostate is heterogeneous and may require a risk-adjusted approach to therapy. Improved survival rates are reported for adjuvant chemotherapy alone or in combination with hormone therapy. A specific gene expression signature can be used to identify and predict response to adjuvant standard hormone therapy or hormone therapy and chemotherapy after radical prostatectomy.
Service d'Urologie, Hôpital Henri Mondor, Créteil, France. bepaule@wanadoo.fr
Bernard
B
Paule
Alexandre
A
de la Taille
D017024:Chemotherapy, Adjuvant; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011446:Prospective Studies; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D006728:Hormones